Amikacin Sulfate

CHEMBL4208954 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
781.8 g/mol
LogP
Phase
4

The sulfate salt form of amikacin, an aminoglycoside antibiotic administered by injection or inhalation to treat severe bacterial infections, particularly those caused by multidrug-resistant gram-negative organisms. Drug level monitoring is essential to ensure therapeutic efficacy while minimizing kidney and ear toxicity.

Khối lượng phân tử

781,8000 g/mol

TPSA

498,00 Ų

Lĩnh vực điều trị

Cơ chế tác dụng

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O.O=S(=O)(O)O.O=S(=O)(O)O

InChI

InChI=1S/C22H43N5O13.2H2O4S/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21;2*1-5(2,3)4/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36);2*(H2,1,2,3,4)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+;;/m0../s1

Molecular Formula

C22H47N5O21S2

HBD / HBA

17 / 25

Liên kết có thể quay

10

Nguyên tử nặng

50

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

The sulfate salt form of amikacin, an aminoglycoside antibiotic administered by injection or inhalation to treat severe bacterial infections, particularly those caused by multidrug-resistant gram-negative organisms. Drug level monitoring is essential to ensure therapeutic efficacy while minimizing kidney and ear toxicity.

Binds irreversibly to the 30S ribosomal subunit, causing misreading of mRNA codons and inhibition of translocation. This leads to production of aberrant proteins and disruption of the bacterial cell membrane.

Yes, Amikacin Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4208954. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 38351. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.